Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL115 in advanced solid tumors
NCT07131189Phase 1Active, not recruiting
- Sponsor
- Forlong Biotechnology
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FL-115 in solid tumor, sponsored by Forlong Biotechnology. Primary endpoints: Safety and tolerability at 8 months, Maximum Tolerated Dose at 18 months and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
FL-115
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07131189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131189.